TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03122002

Intervention type: DRUG
Intervention: Drug Therapy
Description: For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine Blood Test and Image Scan
Description: Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine Blood Test and Image Scan
Description: Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)

Intervention type: OTHER
Intervention: Intravascular therapy
Description: Intravascular therapy including thrombectomy

Intervention type: OTHER
Intervention: Emergency Treatment
Description: Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.

Intervention type: OTHER
Intervention: Medical history
Description: Medical history including hypertension, diabetes, hyperlipemia and ect.

Intervention type: OTHER
Intervention: Medical history
Description: Medical history including hypertension, diabetes, hyperlipemia and ect.
Study: NCT00324805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine Tartrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Given IV
Study: NCT04275713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is an oral antidiabetic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 given intravenously once a week, maximum 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 given intravenously once a week, maximum 6 cycles
Study: NCT04489238

Intervention type: OTHER
Intervention: Risk Factor Questionnaire
Description: Participants, both cases and controls, will complete the CYOC risk factor questionnaire, preferably at the time of first visit

Intervention type: OTHER
Intervention: Risk Factor Questionnaire
Description: Participants, both cases and controls, will complete the CYOC risk factor questionnaire, preferably at the time of first visit
Study: NCT06312436

Intervention type: PROCEDURE
Intervention: Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)
Description: Temporary aortic occlusion can limit haemorrhage, can help to maintain perfusion to the heart and brain, and may be associated with improved survival.
Study: NCT04427384

Intervention type: DEVICE
Intervention: GammaTile
Description: Surgically Targeted Radiation Therapy
Study: NCT03212170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging
Description: 18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer
Study: NCT06075979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar disc herniation
Description: Patients undergoing surgery for lumbar disc herniation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar disc herniation
Description: Patients undergoing surgery for lumbar disc herniation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar spinal stenosis
Description: Patients undergoing surgery for lumbar spinal stenosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar spinal stenosis
Description: Patients undergoing surgery for lumbar spinal stenosis
Study: NCT05815953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polarstem
Description: Stem used in total hip replacement. Manufacturer: Smith \& Nephew Orthopaedics AG, Baar, Switzerland.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corail
Description: Stem used in total hip replacement. Manufacturer: De Puy Int Ltd, Leeds, UK.
Study: NCT02309125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate progressive loading using gingival formers
Description: Implant placement will be 1 mm subcrestally, and it will receive transmucosal healing using gingival former.~The gingival former will be replaced every 2 weeks by consequent larger size gingival former (at surgery time group A will receive 2 mm height gingival former which will be swapped by,3 mm, 4 mm and the last is 5 mm).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: submerged healing
Description: the implant placement will be 1 mm subcrestally, and it will receive unloaded healing.(submerged healing)
Study: NCT00169104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: 5 mcgm/kg daily Monday through Friday weeks 3-14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: G-CSF
Description: 5 mcgm/kg daily Monday through Friday weeks 3-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: 4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: trastuzumab
Description: 4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine
Description: 25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vinorelbine
Description: 25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: 5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
Study: NCT04164797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar+chemoradiotherapy
Description: antiangiogenic drug+chemoradiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiotherapy
Description: chemoradiotherapy
Study: NCT01873118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RN-RHDS protocol
Description: The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RN-RHDS+PT-RHDS protocol
Description: The discharging nurse obtains and reviews patient self-report of discharge readiness using the Readiness for Hospital Discharge Scale - Patient version and then completes the Readiness for Hospital Discharge Scale (RN version)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RN-RHDS + PT-RHDS + NIAF
Description: The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)after reviewing the patients self-perception of discharge readiness (PT-RHDS) and then records any actions taken in response to the discharge readiness assessment on the Nurse Initiated Action form (NIAF). When any item on the RN-RHDS is less than 7, an action is required.
Study: NCT02815033

Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 11C or 18F-Choline PET/CT

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Whole body MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone scan
Study: NCT01373034

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Dietary Fiber
Description: Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice powder
Description: Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
Study: NCT06017544

Intervention type: PROCEDURE
Intervention: PCI
Description: The T2DM affected by AMI will be referred for receiving PCI.
Study: NCT02855801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: constant exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: constant exercise
Study: NCT00638365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB001
Description: Single-dose, 3mg/kg or 10mg/kg dose administered intravenously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single-dose administered intravenously
Study: NCT04302779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solid Model
Description: Cupcakes will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating drying and discrimination tests 'which is the stronger in drying'). Measuring mucoadhesion via protein content remaining in saliva samples following consumption of cupcakes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liquid Model
Description: To study the perception of whey protein beverages using repeated consumption sensory methods (e.g. rating mouthdrying over repeated sips of the drink).
Study: NCT01132118

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.
Study: NCT04535908

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Hypofractionated radiotherapy in prostate cancer patients
Study: NCT01455753

Intervention type: OTHER
Intervention: Functional Proximity
Description: Using each employee's building entry/exit swipe card data, we test whether functional proximity-the likelihood that the employee walks by the clinic for reasons other than vaccination-predicts whether the employee gets vaccinated at the clinic.

Intervention type: OTHER
Intervention: Base Proximity
Description: We also test whether base proximity-the inverse of walking distance from the employee's desk to the clinic-predicts vaccination probability.
Study: NCT04552574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMR(Home meal replacement)-type omega-3-balanced diet
Description: A diet of which omega-3 to omega-6 ratio is below 1:4 was developed by Agricultural entity Green Grass Co., Ltd.. A committee of experts that is composed of several university professors in authorities of IPET(Institute of Planning and Evaluation for Technology in food, agriculture and forestry) also participated in the development of this diet.
Study: NCT00287118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.
Study: NCT02855801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Study: NCT01189825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate to intense cardiovascular exercise on a treadmill for 20 minutes
Study: NCT06101836

Intervention type: OTHER
Group type: OTHER
Intervention: Training intervention
Description: Trainees underwent a one-day training course (intervention) by consciously competent endoscopists who were physically remote consisting of interactive theoretical sessions and live sessions, where trainees performed colonoscopy in their local endoscopy unit receiving real-time instructions via a tele-conference monitor. Trainers and trainees not doing the colonoscopy, followed the procedure in real-time. KPIs were assessed on trainee-performed colonoscopies for 3 weeks prior and 4 weeks after the intervention.
Study: NCT02703077

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spyglass
Description: Endoscopic direct view of the bile ducts
Study: NCT02855801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent exercise
Study: NCT04133597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: social media stimuli (Line app)
Description: social media stimuli (Line app) with texting messages or calls
Study: NCT00411723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTL1000 (recombinant T cell receptor ligand)
Description: Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RTL1000 Placebo
Description: Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.
Study: NCT04308876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy includes techniques applied to elbow joints and surrounding tissues

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: Strengthening exercises used in this study includes resistant exercises to increase muscle strength of upper extremity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercises
Description: Strengthening exercises used in this study includes resistant exercises to increase muscle strength of upper extremity
Study: NCT02762071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Nerve Block
Description: Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
Study: NCT00549796

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Patients undergo routine, clinically indicated PCI

Intervention type: OTHER
Group type: OTHER
Intervention: Percutaneous coronary intervention (PCI)
Description: Patients undergo routine, clinically indicated PCI
Study: NCT02594917

Intervention type: PROCEDURE
Intervention: Right Heart Catheterization
Description: Some participants (i.e., those that are willing and able) will undergo a Right Heart Catheterization to check Cardiopulmonary function.

Intervention type: OTHER
Intervention: Blood draw
Description: Test and control group will be asked to give 20 ml of blood samples

Intervention type: OTHER
Intervention: Blood draw
Description: Test and control group will be asked to give 20 ml of blood samples
Study: NCT02896569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical combination therapy
Study: NCT01438242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genecept Assay
Description: Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genecept Assay
Description: Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
Study: NCT01300247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Participants will receive 6 cycles (each 28-day cycle) of fludarabine at dose of 25 mg/m\^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Participants will receive 6 cycles (each 28-day cycle) of bendamustine at dose of 90 mg/m\^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m\^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
Study: NCT02768792

Intervention type: DRUG
Group type: OTHER
Intervention: pembrolizumab,
Description: Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
Study: NCT04611568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational and training material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational lecture

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive melanoma curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Campaign
Description: View digital media strategies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT02279290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Mind Intervention (HMI)
Description: Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Body Intervention (HBI)
Description: The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
Study: NCT02783274

Intervention type: DEVICE
Group type: OTHER
Intervention: Actis Total Hip System
Description: Total Hip Replacement and Hemi-hip Replacement
Study: NCT03589846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grass S88 Muscle Stimulator
Description: The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. Under anesthesia, fine-wire electrodes will be placed into the right genioglossus muscle (in the floor of the mouth) and the right palatoglossus muscle (in the anterior tonsillar pillar).
Study: NCT03828513

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula oxygen is applied
Description: Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after High flow nasal cannula oxygen. Pulmonary function tests and blood gas parameters are compared.During the procedure, the patient's blood pressure, heart rate, oxygen saturation, any complications that may develop will be recorded.Induction of anesthesia; difficult airway management, difficult mask and / or difficult intubation incidence, Mallampati scores, the use of one of the difficult intubation techniques during intubation, perioperative mechanical ventilation parameters (ventilation mode, tidal volume, respiratory frequency, end of tidal CO2 (carbon dioxide) pressure, PEEP usage, SpO2 (saturation oxygen), airway peak pressure, urine volume, arterial blood gas parameters are recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula oxygen is not applied
Description: Apply preoxygenation with facemask. Prior to induction of general anesthesia, preoxygenation will be applied with an oxygen supplement of 5 l / min to an endtidal O2\> 90%.Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after preoxygenation.
Study: NCT03587311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT03915964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF Inhibitor
Description: Administered SC
Study: NCT04524364

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsed Field Ablation (PFA) Therapy
Description: Participants will undergo PFA therapy with a compatible ablation catheter when used with Multi-Channel irreversible electroporation (IRE) Generator (deliver trains of high-voltage bipolar pulses of short duration on separate channels to a multi-electrode ablation catheter) and Circular IRE Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with an IRE Generator, for cardiac ablation).
Study: NCT01051635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMP400
Description: Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMP776
Description: Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
Study: NCT03141060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Administered orally; dosing will be based on participants' age and weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized multidrug background regimen (OBR) for children with MDR-TB
Description: Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.